Table 1: Pfs ingredients, standardization and in vivo Cyp3a4 modulation.
| PFS-1 Composition* | In vivo CYP3A4 Modulation | Standardization of Active Compounds | PFS-2 Composition# | In vivo CYP3A4 Modulation | Standardization of Active Compounds |
|---|---|---|---|---|---|
| Ginkgo biloba L. dried extract from leaves | CYP3A inhibition in rats [16,17]; slight CYP3A induction in humans [18,19]; CYP3A4 inhibition in humans [20] | 24% Ginkgo flavonoids, 5% terpenes lattons | Perilla frutescens L. dried extract from leaves and seeds | 2.5% total polyphenols | |
| Schisandra chinensis Turcz. dried extract from fruits | CYP3A4 induction in rats [21] | 5% schizandrin | Scutellaria baicalensis Georgi root extract | Baicalin inhibits CYP3A4 in rats [22] | 30% baicalein |
| Camellia sinensis Kuntze (green tea) | CYP3A inhibitor [23]; potent inhibitor CYP3A4 [24,25] | 95% total polyphenols | Citrus x sinensis L. | The aglycone of hesperidin (hesperetin) inhibitis CYP3A4 in rats [26] | 60% hesperidin |
*Composition included vitamin B12 (0.1%) and DL-phosphoserine; #Composition included quercetin and maltodestrine from Zea mays L.